Advertisement
Organon BioSciences is comprised mainly of Organon, the humanpharmaceutical business, and Intervet, the animal health business. It alsoincludes Nobilon, the human vaccine development unit, and Diosynth, the third-party manufacturing unit of Organon.
Advertisement
In connection with the conditional clearance, Schering-Plough and Intervetwill divest three poultry vaccines in the United States. The divestitures arenot material to the company's financial results. No divestitures of humanhealth products are required.
Schering-Plough received approval from The European Commission onOct. 11, 2007, and continues to expect the transaction to be completed byyear-end 2007.
Schering-Plough is a global science-based health care company with leadingprescription, consumer and animal health products. Through internal researchand collaborations with partners, Schering-Plough discovers, develops,manufactures and markets advanced drug therapies to meet important medicalneeds. Schering-Plough's vision is to earn the trust of the physicians,patients and customers served by its approximately 33,500 people around theworld. The company is based in Kenilworth, N.J., and its Web site iswww.schering-plough.com.
DISCLOSURE NOTICE: The information in this press release includes certain"forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995, including statements relating to the company'splans, future actions and expected timelines. Forward-looking statementsrelate to expectations or forecasts of future events. Schering-Plough does notassume the obligation to update any forward-looking statement. Many factorscould cause actual results to differ materially from Schering-Plough'sforward-looking statements, including obtaining regulatory approvals,inaccurate assumptions, market forces, economic factors, the regulatoryprocess, and any developments following regulatory approval, among otheruncertainties. For further details of these and other risks and uncertaintiesthat may impact forward-looking statements, see Schering-Plough's Securitiesand Exchange Commission filings, including Part II, Item 1A, "Risk Factors" inthe Schering-Plough's third quarter 2007 10-Q.
SOURCE Schering-Plough Corporation
